JAZZ Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $4.9M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| GALA RENEE D | President & CEO | Sell 10b5-1 | 2,000 | $243.03 | $486.1K | 143,394 −1.4% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 6,000 | $250.13 | $1.5M | 351,875 −1.7% of holding | |
| Iannone Robert 6 fills | EVP, Global Head of R&D & CMO | Sell 10b5-1 | 76,921 | $249.70 | $19.2M | 124,420 −38.2% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 6,000 | $252.98 | $1.5M | 360,682 −1.6% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 6,000 | $240.47 | $1.4M | 366,682 −1.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.